Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24443126 | 0.98 | MAPT (0.47) | SMN1; SMN2MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL16373659 | 0.98 | MAPT (0.47) | SMN1; SMN2MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL21600414 | 0.90 | MAPT (0.43) | SMN1; SMN2MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL16364863 | 0.88 | LMNA (0.45) | SMN1; SMN2MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL22448436 | 0.86 | MAPT (0.39) | SMN1; SMN2MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL24860142 | 0.84 | MAPT (0.39) | SMN1; SMN2MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL23816806 | 0.84 | KMO (0.42) | SMN1; SMN2MAPTALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL19421378 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTALDH1A1POLBNPC1 | |
| SCHEMBL22898732 | 0.82 | MAPT (0.34) | SMN1; SMN2MAPTALDH1A1POLBNPC1 | |
| SCHEMBL18901095 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPTALDH1A1L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11552258-B2 | Organic light-emitting device comprising emission layer satisfying specific singlet excitation energy level conditions | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11552258-B2 | Organic light-emitting device comprising emission layer satisfying specific singlet excitation energy level conditions | EML4, NES, TBL2 | SMN1; SMN2 1179/4885MAPT 141/4885ALDH1A1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.